Author: Byron L. Lam (United States)
Co-authors: Robert E. MacLaren, M. Dominik Fischer, Frank G. Holz, Mark E. Pennesi, David Birch, Eeva-Marja Sankila
Purpose
Choroideremia is a rare inherited retinal disease that leads to progressive vision loss and eventual blindness, with no currently approved treatments. A clearer understanding of the natural progression of choroideremia is critical for appreciating the potential impact of investigational therapies. Previously, we reported results from an interim cut of the data from 2019. Here, we report results from an interim cut of the data from 2020, which includes the full study population.
Setting/Venue
NIGHT (NCT03359551) was a 2-year, prospective, multicenter, observational study investigating the natural progression of choroideremia.
Methods
NIGHT enrolled adult males with genetically confirmed choroideremia and active disease visible within the macula. At baseline, eyes were classified into 3 cohorts by best-corrected visual acuity (BCVA): ≥74 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (197 eyes), 34-73 ETDRS letters (381 eyes), and <34 ETDRS letters (53 eyes). Visits occurred at 4-month intervals; BCVA, preserved ellipsoid zone (EZ) area, preserved area of autofluorescence (PAF), microperimetry (MP), contrast sensitivity, color vision, and reading-speed tests were assessed periodically. Endpoints other than BCVA were assessed through 12 months.
Results
NIGHT enrolled adult males with genetically confirmed choroideremia and active disease visible within the macula. At baseline, eyes were classified into 3 cohorts by best-corrected visual acuity (BCVA): ≥74 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (197 eyes), 34-73 ETDRS letters (381 eyes), and <34 ETDRS letters (53 eyes). Visits occurred at 4-month intervals; BCVA, preserved ellipsoid zone (EZ) area, preserved area of autofluorescence (PAF), microperimetry (MP), contrast sensitivity, color vision, and reading-speed tests were assessed periodically. Endpoints other than BCVA were assessed through 12 months.
Conlusions
Updated analyses of all enrolled participants in the NIGHT study were consistent with initial results describing gradual vision loss in individuals with choroideremia. Older participants tended to experience a greater decline in vision by BCVA over 20 months compared with younger participants. Microperimetry sensitivity, preserved EZ area, and PAF decreased over 12 months in all cohorts. These results reaffirm the importance of BCVA, MP, preserved EZ area, and PAF as measures of the natural progression of choroideremia.
Financial Disclosure
Editorial support was provided by MedThink SciCom and funded by Biogen. BLL: Biogen (grant support, consultant); REM: Biogen (grant support, consultant, named inventor on BIIB112 patent licensed by the University of Oxford); MDF: Biogen (grant support, consultant, clinical trial support); FGH: NightStarX (financial support); MEP: Biogen (consultant, clinical trial support); DB: Biogen (financial support); E-MS: Biogen (consultant); IAM: Nothing to disclose; KS: Biogen (clinical trial support) JMFS: Biogen (consultant); GZ and DY: Biogen (employees and may hold stock or stock options in the company)
Comments
Additional co-authors: 7. Isabelle Anne Meunier - Montpellier University Hospital Center, Montpellier, France 8. Kimberly Stepien - University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 9. Juliana Maria Ferraz Sallum - Universidade Federal de São Paulo, São Paulo, Brazil 10. Guolin Zhao - Biogen, Cambridge, MA, USA 11. Dan Yoon - Biogen, Cambridge, MA, USA